Chronic Inducible Urticaria is a group of chronic urticarias characterized by the appearance of recurrent wheals, recurrent angioedema, or both, as a response to specific triggers.
How has Chronic Inducible Urticaria impacted people's lives?
- The total Chronic Inducible Urticaria prevalent population in 7MM was 652,542 in 2017.
- The total prevalent cases for Chronic Inducible Urticaria were highest in the United States, followed by Germany and France among 7MM countries.
- About 50% of cases of Chronic Inducible Urticaria are symptomatic dermographism, and 20% each are cold urticaria and cholinergic urticaria; the other 10% are the different forms of Chronic Inducible Urticaria.
How will Disease transform Chronic Inducible Urticaria Market?
The market size of Chronic Inducible Urticaria is anticipated to rise at a significant CAGR during the study period of 2017–2030. Among all 7MM, the United States accounted for the largest Chronic Inducible Urticaria market size.
Among EU5 countries, Germany had the largest market size of Chronic Inducible Urticaria, with USD 172 million in 2017, while Spain had the smallest Chronic Inducible Urticaria market size with USD 104.5 million in 2017.
Chronic Inducible Urticaria market drivers
- Need for curative therapy
- Increasing awareness
- Rising prevalence
Chronic Inducible Urticaria market barriers
- Need for biomarkers
- Complex pathophysiology
- Patient adherence
- Need for Chronic Inducible Urticaria specific population studies
Which biotechnical companies are developing Chronic Inducible Urticaria drugs?
The therapeutic goal of Chronic Inducible Urticaria management primarily focuses on achieving complete symptom control by trigger avoidance and desensitization, blocking the effects of mast cell mediators (non- sedating, second-generation antihistamines), and prevention of mast cell degranulation. Currently, there is no approved therapy for Chronic Inducible Urticaria treatment apart from symptomatic management. The pipeline scenario does not show a particularly close picture with only one major player making significant inroads in the largely untapped market. AK002 (Antolimab), being developed by Allakos Pharma, is the only drug with the potential to enter the arena during the forecast period and has completed Phase II trials.